State-of-the-art photodynamic therapy for malignant gliomas: innovations in photosensitizers and combined therapeutic approaches DOI Creative Commons
Bruno Agustín Cesca,

K. Martin,

Matías Daniel Caverzán

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Glioblastoma (GBM), the most aggressive and lethal primary brain tumor, poses a significant therapeutic challenge due to its highly invasive nature resistance conventional therapies, including surgery, chemotherapy, radiotherapy. Despite advances in standard treatments, patient survival remains limited, requiring exploration of innovative strategies. Photodynamic therapy (PDT) has emerged as promising approach, leveraging light-sensitive photosensitizers (PSs), molecular oxygen, specific light wavelengths generate reactive oxygen species (ROS) that selectively induce tumor cell death. Originally developed for skin cancer, PDT evolved target more complex malignancies, GBM. The refinement second- third-generation PS, coupled with advancements nanotechnology, significantly improved PDT's selectivity, bioavailability, efficacy. Moreover, combination targeted therapy, immunotherapy, among other modalities, shown potential enhancing outcomes. This review provides comprehensive analysis preclinical clinical applications GBM, detailing mechanisms action, evolution novel combinatory strategies optimize treatment However, several challenges remain, overcoming GBM-associated hypoxia, PS delivery across blood-brain barrier, mitigating mechanisms. integration genetic insight, alongside cutting-edge nanotechnology-based systems, may revolutionize GBM treatment, offering new prospects quality life.

Language: Английский

Biomimetic Atorvastatin Self-Assembled Nanomedicine Inhibit the Cyclooxygenase-2/prostaglandin E2 Pathway Enhanced Photothermal and Antitumor Immunity DOI Creative Commons
Min Zhou, Ruyue Han, Wenjie Xu

et al.

Biomaterials Research, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 3, 2025

Cancer continues to pose remarkable medical challenges worldwide. While current cancer therapies can lead initial clinical improvement, they are often followed by recurrence, metastasis, and drug resistance, underscoring the urgent need for innovative treatment strategies. Atorvastatin calcium (AC), a widely used lipid-lowering anti-inflammation in clinic, has shown antitumor potential. To further improve efficacy, we developed self-assembled AC polydopamine (PDA) nanoparticles whose surface was coated with macrophage membranes (CM) as biomimetic delivery system [AC@PDA@CM (APM)]. APM showed high drug-loading capacity, excellent stability, bioavailability, tumor-targeting ability, ultimately achieving photothermal synergistic immunotherapy. Our findings indicate that efficiently delivers tumor sites while leveraging therapy (PTT) enhance local ablation immune effect. Notably, mitigates immunosuppression triggered PTT through AC, suppressing COX-2/PGE2 pathway evasion signal CD47. Furthermore, notably reduced nonspecific distribution side effects, which is conducive ensuring safety level of medication. This integrated approach boosts therapeutic efficacy highlights potential multifunctional agent therapy, paving way future applications.

Language: Английский

Citations

0
State-of-the-art photodynamic therapy for malignant gliomas: innovations in photosensitizers and combined therapeutic approaches DOI Creative Commons
Bruno Agustín Cesca,

K. Martin,

Matías Daniel Caverzán

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Glioblastoma (GBM), the most aggressive and lethal primary brain tumor, poses a significant therapeutic challenge due to its highly invasive nature resistance conventional therapies, including surgery, chemotherapy, radiotherapy. Despite advances in standard treatments, patient survival remains limited, requiring exploration of innovative strategies. Photodynamic therapy (PDT) has emerged as promising approach, leveraging light-sensitive photosensitizers (PSs), molecular oxygen, specific light wavelengths generate reactive oxygen species (ROS) that selectively induce tumor cell death. Originally developed for skin cancer, PDT evolved target more complex malignancies, GBM. The refinement second- third-generation PS, coupled with advancements nanotechnology, significantly improved PDT's selectivity, bioavailability, efficacy. Moreover, combination targeted therapy, immunotherapy, among other modalities, shown potential enhancing outcomes. This review provides comprehensive analysis preclinical clinical applications GBM, detailing mechanisms action, evolution novel combinatory strategies optimize treatment However, several challenges remain, overcoming GBM-associated hypoxia, PS delivery across blood-brain barrier, mitigating mechanisms. integration genetic insight, alongside cutting-edge nanotechnology-based systems, may revolutionize GBM treatment, offering new prospects quality life.

Language: Английский

Citations

0